Using ddPCR for Fast, Cost-Effective Test
The researchers applied Bio-Rad's ddPCR technology to quantify graft-derived cfDNA in recent liver transplant patients and in stable patients who had undergone a transplant procedure more than six months earlier. ddPCR technology allowed them to develop a cost-effective and fast laboratory test that detects cfDNA being released into the blood stream by dying cells from the transplanted organ.
"GcfDNA from dying graft cells are the most direct and sensitive indicator of organ rejection and we needed an instrument that could measure it," said Chronix Biomedical's Chief Technology Officer and the study's senior author, Ekkehard Schuetz, MD, PhD. "ddPCR added an additional level of reliability and precision to traditional PCR."
Sequencing methods typically require batch sampling, but by using ddPCR, researchers are able to run single samples. Additionally, this method is reducing test time from three days or more to one day and costs by 90 percent. The study authors were able to address the need for donor DNA by preselecting SNPs that ensure enough heterogeneity between donor and recipient. The new blood test can also deliver results up to several days before the conventional aspartate aminotransferase (AST) and bilirubin tests for liver transplantation rejection, with the potential for an immediate positive impact on patient care.
"We will now be able to detect subclinical rejection and early intervention may allow us to avoid a full-blown rejection," said Michael Oellerich, M.D., FACB, FRCPath and Lower Saxony Distinguished Professor of Clinical Chemistry at the University Medical Center Gttingen and study Principal Investigator. "This test may be useful to personalize immunosuppression and to improve long-term outcomes."
"Detecting non-host cfDNA is the third example for the commercial potential of cfDNA diagnostics. Researchers will now be able to ex
|Contact: Ken Li|